abrocitinib
Sponsor Pfizer INC · listed as PFE
abrocitinib is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected May 2, 2027 (day precision, medium confidence), tied to trial NCT06807268. That trial is in Phase 3 and currently recruiting, studying Eczema. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for abrocitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06807268 catalyst | Phase 3 | Recruiting | 2027-05-02 | Experimental | Pfizer | Eczema |
| NCT07823595 | Phase 3 | Not yet recruiting | 2029-04-10 | Experimental | Pfizer | Atopic Dermatitis |
| NCT06807281 | Phase 3 | Recruiting | 2032-02-22 | Experimental | Pfizer | Atopic Dermatitis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts